| Table 3. Cutoff Value of Each Tumor Marker According to Tumor Stage | ||||||
|
|
||||||
|
Tumor stage
|
||||||
|
|
||||||
|
I
|
II
|
III
|
IV
|
V
|
||
|
Tumor marker
|
(N)
|
(m-)
|
(M2-)
|
(G0-)
|
(G1-)
|
|
|
|
||||||
|
CEA (ng/ml)
|
<2.9
|
3.0-3.5
|
3.5-3.9
|
4.0-4.3
|
>4.4
|
|
|
IAP (mg/ml)
|
<299
|
300-449
|
450-499
|
450-499
|
>500
|
|
|
RNase (units)
|
60-69
|
70-89
|
90-109 or <59
|
110-144 or -59
|
>145 or <59
|
|
|
Sialic acid (mg/dl)
|
45-59
|
45-59
|
60-65
|
>66
|
>66
|
|
|
FT (ng/ml)
|
||||||
|
Male
|
55-99
|
100-199
|
200-249
|
250-299
|
>300
|
|
|
Female
|
30-79
|
80-149
|
150-179
|
180-199
|
>200
|
|
|
FT/Fe
|
1-1.99
|
1-1.99
|
2-4.99
|
5-9.99 or <0.9
|
>10 or <0.9
|
|
|
HSAP (U/I)
|
<9.9
|
<9.9
|
10-19.9
|
20-36.9
|
>37
|
|
|
CA19-9 (U/ml)
|
<29
|
30-32
|
33-34
|
35-36
|
>37
|
|
|
TPA (U/I)
|
<74
|
75-79
|
80-84
|
85-109
|
>110
|
|
|
ALP isoenzymes
|
||||||
|
ALP1 (%)
|
0
|
0
|
0
|
1-4
|
<5
|
|
|
ALP2/3 ratio
|
1.0-1.9
|
1.0-1.9
|
<0.9 or 2.0-2.4
|
<0.9 or 2.0-2.4
|
<0.9 or >2.5 >0.1
|
|
|
APA
|
<0.09
|
<0.09
|
<0.09
|
>0.1
|
>0.1
|
|
|
|
||||||
Results
Distribution of Each Tumor Stage
Figure 1 shows the distribution of subjects grouped by tumor stage. The number of subjects at each tumor stage was a follows: Stage I, 2 (0.1%); Stage II, 250 (11.8%); Stage III, 1251 (58.8%); Stage IV, 528 (24.8%); Stage V, 95 (4.5%). although a few differences i the distribution were found in each geographic area, the mean of the rates in each area (among seven selected areas, mean ± standard deviation: I, 0.1 ± 0.4; II, 15.8 ± 10.3; III, 57.3 ± 7.2; IV, 24.8 ± 8.9; V, 2.0 2.0%) was similar to that of the total 2126 subjects.
TUMOR STAGES
Figure 1. Distribution of subjects by tumor stage. For the classification of stages, see Figure 4.
The tumor stage distribution of the 2126 subjects in four different age groups
is shown in Figure 2. The age distribution of our screenees appears to be similar
to that of conventional mass cancer screening in Japan (Table 2). As shown in Figure
2, the percentage of subjects in Stage III was always maximum, showing a slow decrease
with age. The percentage of subjects decreased with age in tumor stage II, whereas
it increased in tumor stages IV and V.
Cancer Incidence of Each Stage
Twenty-eight of 95 Stage V (29.5%), 14 of 528 Stage IV (2.7%, 9 of 1251 Stage III (0.7%), 1 of 250 Stage II (0.4%), and 0 of 2 Stage I (0.0%) subjects were finally diagnosed as having cancer (cancer sites: lung, 10: breast, 10: stomach, 7; colorectom, 6; uterus, 2; urinary bladder, 1; oral cavity, 2; esophagus, 1; pancreas, 1; bone,1; tongue,1; prostate, 1; gallbaldder,1; larynx 1; ovary, 1; brain, 1; cervical occipital, 1; thyroid cancer, 1; and other, 3 subjects [total, 52]).
Figure 2. Distribution of subjects in each stage by age group. Cancer screening
was conducted among randomly selected subjects (N = 2126; male, 1091; female, 1035)
of 15 areas. 
Stage II, 
Stage III, 
Stage IV, 
Stage V.